3/4
04:05 pm
svra
Savara Announces Participation in 2026 Citizens Life Sciences Conference
Low
Report
Savara Announces Participation in 2026 Citizens Life Sciences Conference
3/1
07:53 pm
svra
Savara Highlights FDA Priority Review for Molbreevi as Aug. 22 PDUFA Date Nears [Yahoo! Finance]
Low
Report
Savara Highlights FDA Priority Review for Molbreevi as Aug. 22 PDUFA Date Nears [Yahoo! Finance]
2/20
04:15 pm
svra
Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Medium
Report
Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
2/13
04:05 pm
svra
Savara Announces New Employment Inducement Grant
Low
Report
Savara Announces New Employment Inducement Grant
2/4
04:05 pm
svra
Savara Announces Participation in Upcoming Investor Healthcare Conferences
Medium
Report
Savara Announces Participation in Upcoming Investor Healthcare Conferences
1/27
08:05 am
svra
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*
Low
Report
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*
1/24
11:38 am
svra
SAVARA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Savara, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Medium
Report
SAVARA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Savara, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
1/16
04:05 pm
svra
Savara Announces New Employment Inducement Grant
Low
Report
Savara Announces New Employment Inducement Grant
1/11
09:22 am
svra
With 37% stake, Savara Inc. (NASDAQ:SVRA) seems to have captured institutional investors' interest [Yahoo! Finance]
Low
Report
With 37% stake, Savara Inc. (NASDAQ:SVRA) seems to have captured institutional investors' interest [Yahoo! Finance]
1/8
04:27 pm
svra
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI* [Yahoo! Finance]
Low
Report
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI* [Yahoo! Finance]
1/8
04:05 pm
svra
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*
Low
Report
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*
12/23
10:13 am
svra
Savara (NASDAQ:SVRA) was given a new $10.00 price target on by analysts at Oppenheimer Holdings, Inc..
Low
Report
Savara (NASDAQ:SVRA) was given a new $10.00 price target on by analysts at Oppenheimer Holdings, Inc..
12/23
10:13 am
svra
Savara (NASDAQ:SVRA) was given a new $10.00 price target on by analysts at UBS Group AG.
Low
Report
Savara (NASDAQ:SVRA) was given a new $10.00 price target on by analysts at UBS Group AG.
12/23
08:42 am
svra
Savara (NASDAQ:SVRA) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Savara (NASDAQ:SVRA) had its "buy" rating reaffirmed by analysts at Guggenheim.
12/23
07:17 am
svra
Savara (NASDAQ:SVRA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Savara (NASDAQ:SVRA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/22
09:05 am
svra
Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) [Yahoo! Finance]
Medium
Report
Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) [Yahoo! Finance]
12/22
08:30 am
svra
Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Medium
Report
Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
12/18
10:26 am
svra
Savara (NASDAQ:SVRA) had its price target raised by analysts at Wells Fargo & Company from $7.00 to $9.00. They now have an "overweight" rating on the stock.
Low
Report
Savara (NASDAQ:SVRA) had its price target raised by analysts at Wells Fargo & Company from $7.00 to $9.00. They now have an "overweight" rating on the stock.
12/17
08:05 am
svra
Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
12/11
08:55 am
svra
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI* [Yahoo! Finance]
Low
Report
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI* [Yahoo! Finance]
12/11
08:05 am
svra
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*
Medium
Report
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*